Signaling-specific inhibition of the CB(1) receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.

Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV

Open source

DOI: 10.1038/s41591-023-02381-w
Published: 2023 Jun
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02381-w,
  title = {Signaling-specific inhibition of the CB(1) receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.},
  author = {Haney M and Vallée M and Fabre S and Collins Reed S and Zanese M and Campistron G and Arout CA and Foltin RW and Cooper ZD and Kearney-Ramos T and Metna M and Justinova Z and Schindler C and Hebert-Chatelain E and Bellocchio L and Cathala A and Bari A and Serrat R and Finlay DB and Caraci F and Redon B and Martín-García E and Busquets-Garcia A and Matias I and Levin FR and Felpin FX and Simon N and Cota D and Spampinato U and Maldonado R and Shaham Y and Glass M and Thomsen LL and Mengel H and Marsicano G and Monlezun S and Revest JM and Piazza PV},
  year = {2023},
  journal = {Nature medicine},
  doi = {10.1038/s41591-023-02381-w},
  url = {https://doi.org/10.1038/s41591-023-02381-w}
}

RIS

TY  - JOUR
TI  - Signaling-specific inhibition of the CB(1) receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.
AU  - Haney M
AU  - Vallée M
AU  - Fabre S
AU  - Collins Reed S
AU  - Zanese M
AU  - Campistron G
AU  - Arout CA
AU  - Foltin RW
AU  - Cooper ZD
AU  - Kearney-Ramos T
AU  - Metna M
AU  - Justinova Z
AU  - Schindler C
AU  - Hebert-Chatelain E
AU  - Bellocchio L
AU  - Cathala A
AU  - Bari A
AU  - Serrat R
AU  - Finlay DB
AU  - Caraci F
AU  - Redon B
AU  - Martín-García E
AU  - Busquets-Garcia A
AU  - Matias I
AU  - Levin FR
AU  - Felpin FX
AU  - Simon N
AU  - Cota D
AU  - Spampinato U
AU  - Maldonado R
AU  - Shaham Y
AU  - Glass M
AU  - Thomsen LL
AU  - Mengel H
AU  - Marsicano G
AU  - Monlezun S
AU  - Revest JM
AU  - Piazza PV
PY  - 2023
JO  - Nature medicine
DO  - 10.1038/s41591-023-02381-w
UR  - https://doi.org/10.1038/s41591-023-02381-w
ER  -

APA

M, H., M, V., S, F., S, C. R., M, Z., G, C., CA, A., RW, F., ZD, C., T, K., M, M., Z, J., C, S., E, H., L, B., A, C., A, B., R, S., DB, F., F, C., B, R., E, M., A, B., I, M., FR, L., FX, F., N, S., D, C., U, S., R, M., Y, S., M, G., LL, T., H, M., G, M., S, M., JM, R., & PV, P. (2023). Signaling-specific inhibition of the CB(1) receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.. Nature medicine. https://doi.org/10.1038/s41591-023-02381-w

Source records

pubmed · retrieved 2026-09-26T20:26:43.129Z